Teva Pharma and Biolojic Design announces an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of Atopic Dermatitis and Asthma
- Biolojic's BD9 is a multibody that was computationally designed as a multi specific antibody targeting IL-13 / TSLP to treat inflammatory diseases.
- Agreement builds on Teva's Pivot to Growth strategy to step up innovation on Teva's innovative pipeline.
- Teva to obtain exclusive worldwide rights to develop and commercialize BD9 multibody for potential treatment for Atopic Dermatitis and Asthma
No comments:
Post a Comment